Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Equinix | Alibaba Group | Pfizer | |
|---|---|---|---|
| Moat rating | wide The FY2025 10-K (filed 2026-02-11) grounds the advantage in an asset that took 27 years to assemble and that a competitor cannot buy: "Over our 27-year history, we have curated a diverse, industry-leading ecosystem of more than 500,000 interconnections", "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", across "280 data centers, in 77 markets in 36 countries", with "99.9999%+ operational uptime" delivered in 2025 and no single customer at 10% of revenue. Because the value of each IBX rises with who else is already inside it, incumbency compounds rather than decays. The counterweight is real and disclosed: Item 1A says "The global multi-tenant data center market is highly fragmented. It is estimated that we are one of more than 2,400 companies that provide these offerings around the world", and warns that competitors "may adopt aggressive pricing policies". That caps the pricing that the moat converts into, not its durability — the fragmentation sits in commodity space-and-power, while the interconnection density the filing describes has no comparable substitute. FY2025 revenue of $9.217B with operating margin recovering to 20.0% from 15.2% in FY2024 is consistent with the incumbency holding. | wide The FY2026 20-F rests on two entrenched positions: a commerce ecosystem the filing ties to 'the world's largest online retail market' with 'over 1.1 billion Internet users,' and a cloud business whose 'Cloud Intelligence Group's external revenue growth accelerated to 40% in the final quarter of fiscal 2026, with AI-related products accounting for 30% of this revenue.' Two durable franchises under one roof is a wide moat — bounded by China regulation and US ICTS cloud controls the same filing flags. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | network effects The 10-K names the mechanism itself, twice and unprompted: "As more customers choose Equinix for high connectivity and performance reliability at the metro edge, it benefits their suppliers and business partners to colocate in the same data centers and connect directly with each other. This adjacency creates a network effect that attracts new customers while continuously enhancing our value proposition to existing customers", and in the Competitive Landscape section, "This ecosystem creates a network effect that improves performance and lowers the cost for our customers". The evidence is the count of participants rather than any patent or unit-cost claim — 500,000+ interconnections, 2,000+ network service providers, a leading share of cloud on-ramps, an Internet Exchange the filing calls "the largest global peering solution". Switching costs are a genuine second layer (fixed-duration contracts billed on space and power, physical cross connects into resident counterparties), but they are what holds a customer already inside the ecosystem; the reason to enter in the first place is who is already there. | network effects The 20-F names 'the network effects of our ecosystems' among the factors its business depends on: Taobao and Tmall, Alipay, Amap and the rest compound as buyers, sellers and services reinforce each other across one integrated ecosystem. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | clear leader Leadership is claimed on interconnection, not on square footage, and the filing's own evidence is about density: "our position is unmatched in the industry" is supported by 2,000+ resident network service providers, "a leading market share of cloud-on ramps", 500,000+ interconnections and an Internet Exchange described as "the largest global peering solution", across 36 countries. The band is read against neutral, ecosystem-dense colocation, where that footprint has no direct analogue. It is deliberately not read against total data centre capacity: the same 10-K puts Equinix among "more than 2,400 companies" in a "highly fragmented" MTDC market, and Item 1A concedes the company must compete for land and power against "new market entrants" drawn in by AI. | clear leader The 20-F claims leadership in applied AI ('strengthened our leadership in applied AI') and roots the commerce business in the world's largest online retail market; Alibaba Cloud is the leading China hyperscaler pivoting to AI, per the segment discussion — a category leader in both its home markets. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Contract structure supports price: fixed-duration agreements billed on space and power plus per-connection interconnection fees, an installed base too physically entangled to move cheaply, and 99.9999%+ uptime in 2025 as the thing being paid for. FY2025 revenue of $9.217B grew about 5% on FY2024's $8.748B while operating margin recovered to 20.0% from 15.2%, so pricing and cost were at least held. But the filing itself refuses the strong band: competitors "may adopt aggressive pricing policies, especially if they are not highly leveraged or have lower return thresholds than we do. As a result, we may suffer from pricing pressure that would adversely affect our ability to generate revenues", and some rivals bundle communications or cloud services against bare colocation. Power procurement is a further pass-through risk the filing flags. Price is defended, not dictated. | moderate Ecosystem lock-in and cloud scale support pricing, but the filing warns that if 'user activity and engagement in our ecosystem may decrease … our market share and profitability may be negatively affected,' and Chinese e-commerce/cloud competition is intense — real but capped pricing power. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | Equinix is a network-neutral, multi-tenant colocation and interconnection REIT: it does not sell compute, it sells the metro-edge real estate where networks, clouds and enterprises physically meet. The FY2025 10-K describes the platform as "280 data centers, in 77 markets in 36 countries" serving "over 10,500 customers, including 2,000+ network service providers and a leading market share of cloud-on ramps", carrying "more than 500,000 interconnections" curated over 27 years, with 61% of 2025 revenue recognised outside the U.S. Revenue is structurally recurring — infrastructure offerings are "billed based on the space and power a customer consumes" under fixed-duration contracts generating MRR, interconnection is "billed based on the outbound connections from a customer" — and no customer reached 10% of 2025 revenue. AI enters the story as demand rather than as a product: the filing positions Equinix as the interconnect point for "model providers, data platforms, neoclouds and gateways", and pushes core hyperscale capacity into xScale, which is "developed and operated through our joint venture partnership arrangements". The bear case is in the company's own Item 1A. The MTDC market is "highly fragmented", Equinix being "one of more than 2,400 companies"; competitors "may adopt aggressive pricing policies"; the AI build-out invites "significant investments in the data center industry by both current competitors and new investors", after which "we could lose market share" and must "compete against certain of these competitors to secure the land and power needed for our expansion plans". Product extension has also failed before — the filing notes past offerings "have been or are being discontinued, including the Equinix Metal product". The honest reading: the interconnection ecosystem is close to unreplicable and the moat sits there; the capacity business around it is a capital race Equinix enters with scale but no immunity. | Alibaba is a commerce network and an AI cloud fused into one ecosystem. The retail side draws its moat from network effects the filing names explicitly, rooted in the world's largest online retail market; the cloud side is pivoting hard into AI — Alibaba Cloud's 'growth engine fully pivots from traditional compute and storage to models, AI compute, and agent services,' anchored by the in-house Qwen family (Qwen3.7-Max 'specifically engineered for agents') and the PAI platform. The 20-F's own framing is 'leading full-stack capabilities across the AI value chain.' The counterweights are structural rather than competitive: a Cayman VIE structure, China's regulatory environment, and the US Commerce Department's proposed ICTS cloud-computing controls the filing discloses. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Equinix is the neutral meeting point of the AI and cloud supply chain rather than a link in its manufacturing path: it houses other companies' compute and sells the adjacency between them. The 10-K places it between the network layer (2,000+ service providers), the cloud layer ("a leading market share of cloud-on ramps") and enterprise consumers who "assemble these capabilities into operational stacks", and describes an AI ecosystem "of model providers, data platforms, neoclouds and gateways" curated for enterprise AI demand. Core hyperscale training capacity sits beside that, not inside it, in xScale, built with JV partners so hyperscalers "add to their core hyperscale data center deployments and existing customer access points at Equinix". The revenue is therefore levered to AI's distribution and inference edge more than to training-cluster buildout. | Layer-8 hyperscaler + AI-application incumbent: Alibaba Cloud supplies AI compute and the Qwen models while the commerce ecosystem is a vast applied-AI distribution surface. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |